Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream

The brain-computer interface space has long been dominated by two competing philosophies: invasive electrode-based implants that offer high signal fidelity but carry surgical risk, and non-invasive surface approaches that are safer but historically limited in resolution. A new partnership announced today between Merge Labs and Butterfly Network signals a serious industry push to carve out a third path — one built on ultrasound-based neural interfacing.

The Technology

Ultrasound-based BCIs represent one of the more compelling frontiers in neural interface research. Unlike traditional electroencephalography, which reads electrical signals from the scalp with limited spatial precision, functional ultrasound neuroimaging can resolve brain activity at a level of detail that sits meaningfully between surface EEG and implanted electrode arrays. Butterfly Network brings to this partnership its established expertise in handheld, semiconductor-based ultrasound hardware — technology that has already disrupted the diagnostic imaging market by dramatically reducing the cost and footprint of clinical-grade ultrasound devices. Merge Labs, for its part, contributes its software and signal-processing infrastructure designed for neural applications. Together, the companies are positioned to tackle both the hardware miniaturization and the computational decoding challenges that have slowed ultrasound BCIs from laboratory demonstration to practical deployment.

Why This Matters

For the neurotechnology industry, this partnership carries implications that extend well beyond the two companies involved. The dominant narrative in BCI development has been shaped by high-profile implantable programs, which — despite their scientific achievements — face an inherently limited addressable market due to surgical requirements and regulatory complexity. A credible, non-invasive ultrasound alternative, backed by a company with Butterfly Network's track record in scaling medical hardware, could meaningfully expand the population of patients and end-users for whom BCI technology is a realistic option. Clinicians working in neurorehabilitation, communication assistance, and motor restoration have been waiting for a non-invasive modality that does not require them to send patients to the operating room. This collaboration is a direct response to that unmet need.

Market Context

The announcement lands at a moment when investor and regulatory interest in non-invasive neural interfaces is accelerating. Several recent developments — including FDA clearances for neuromodulation devices and growing clinical acceptance of at-home neural health tools — have built a policy and commercial infrastructure that a mature ultrasound BCI product could eventually slot into. Butterfly Network's existing relationships with hospital systems and its familiarity with FDA pathways for ultrasound hardware give this partnership a commercially grounded foundation that pure-play BCI startups often lack.

If Merge Labs and Butterfly Network can translate their combined capabilities into a validated, scalable platform, the partnership may well define the next competitive axis in brain-computer interfaces — one where accessibility, not just performance, becomes the primary measure of progress.